A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 11, Issue 5, 2012, Pages 419-426

  Littlewood, Kavi J ^a   Higashi, Kyoko ^a   Jansen, Jeroen P ^b   Capkun Niggli, Gorana ^c   Balp, Maria Magdalena ^c   Doering, Gerd ^d   Tiddens, Harm A W M ^e   Angyalosi, Gerhild ^c  

^a MAPI GROUP   (Netherlands)

^b MAPI Consultancy   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Institut fur Medizinische Mikrobiologie und Hygiene   (Germany)

^e SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Cystic fibrosis; Inhaled antibiotics; Network metaanalysis; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

AZTREONAM LYSINE; BRAMITOB; COLISTIMETHATE; COLISTIN; PLACEBO; TOBRAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HUMAN; LUNG INFECTION; META ANALYSIS; PSEUDOMONAS AERUGINOSA; SPUTUM ANALYSIS; SYSTEMATIC REVIEW;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; AZTREONAM; BACTERIAL LOAD; BAYES THEOREM; BIOLOGICAL AVAILABILITY; CHRONIC DISEASE; COLISTIN; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFORMATION SERVICES; MALE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84866172783     PISSN: 15691993     EISSN: 18735010     Source Type: Journal    
DOI: 10.1016/j.jcf.2012.03.010     Document Type: Article

References (25)

1. Döring G., Ratjen F. Immunology of cystic fibrosis. Cystic fibrosis 2007, 69-80. Arnold Hammer, London, England. M.E. Hodson, D. Geddes, A. Bush (Eds.).
2. Hoiby N., Frederiksen B. Microbiology of cystic fibrosis. Cystic fibrosis 2000, 83-108. Arnold, London, England. M.E. Hodson, D. Geddes (Eds.).
3. Tsui L.-C. The spectrum of cystic fibrosis mutations. Trends Genet 1992, 8:392-398.
4. Döring G., Gulbins E. Cystic fibrosis and innate immunity: how chloride channel mutations provoke lung disease. Cell Microbiol 2009, 11:208-216.
5. Döring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91. for the Consensus Study Group.
6. Lu G., Ades A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004, 23(20):3105-3124.
7. Jansen J.P., Fleurence R., Devine B., Itzler R., Barrett A., Hawkins N., et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011, 14(4):417-428.
8. Caldwell D.M., Ades A.E., Higgins J.P. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005, 331(7521):897-900.
9. Cooper N.J., Sutton A.J., Morris D., Ades A.E., Welton N.J. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med 2009, 28:1861-1881.
10. Lunn D.J., Thomas A., Best N., Spiegelhalter D. WinBUGS - a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000, 10:325-337.
11. Jensen T., Pedersen S.S., Garne S., Heilmann C., Høiby N., Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother Jun 1987, 19(6):831-838.
12. Ramsey B.W., Pepe M.S., Quan J.M., Otto K.L., Montgomery A.B., Williams-Warren J., et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group. N Engl J Med Jan 7 1999, 340(1):23-30.
13. Hodson M.E., Gallagher C.G., Govan J.R. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J Sep 2002, 20(3):658-664.
14. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease 2008.
15. Nasr S.Z., Sakmar E., Christodoulou E., Eckhardt B.P., Streetman D.S., Strouse P.J. The use of high resolution computerized tomography (HRCT) of the chest in evaluating the effect of tobramycin solution for inhalation in cystic fibrosis lung disease. Pediatr Pulmonol May 2010, 45(5):440-449.
16. Lenoir G., Antypkin Y.G., Miano A., Moretti P., Zanda M., Varoli G., et al. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs 2007, 9(Suppl. 1):11-20.
17. Oermann C.M., Assael B., Nakamura C., Boas S.R., Bresnik M., Montgomery A.B., et al. Aztreonam for inhalation solution (AZLI) vs. tobramycin inhalation solution (TIS): a 6-month comparative trial in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (PA). 24th Annual North American Cystic Fibrosis Conference Oct 2010, Poster 305.
18. Ryan G., Singh M., Dwan K. Inhaled antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev Mar 2011, 16(3). CD001021.
19. Tiddens H.A.W.M., De Jong P.A. Imaging and clinical trials in cystic fibrosis. Proc Am Thorac Soc 2007, 4(4):343-346.
20. Loeve M., van Hal P.T.W., Robinson P., de Jong P.A., Lequin M.H., Hop W.C., et al. The spectrum of structural abnormalities on CT scans from CF patients with severe advanced lung disease. Thorax 2009, 64:876-882.
21. Chuchalin A., Csiszér E., Gyurkovics K., Bartnicka M.T., Sands D., Kapranov N., et al. A formulation of aerosolized tobramycin (TIS-B) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs 2007, 9(Suppl. 1):21-31.
22. Konstan M.W., Flume P.A., Kappler M., Chiron R., Higgins M., Brockhaus F., et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros Jan 2011, 10(1):54-61.
23. Konstan M.W., Geller D.E., Minić P., Brockhaus F., Zhang J., Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011, 46:230-238.
24. McCoy K.S., Quittner A.L., Oermann C.M., Gibson R.L., Retsch-Bogart G.Z., Montgomery A.B. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med Nov 1 2008, 178(9):921-928.
25. Retsch-Bogart G.Z., Quittner A.L., Gibson R.L., Oermann C.M., McCoy K.S., Montgomery A.B., et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest May 2009, 135(5):1223-1232.